Phase III randomized trial of gadolinium texaphyrin (PCI-0120) as a radiosensitizer in patients with brains metastases receiving whole brain radiotherapy
Article
Mehta, M. (2001). Phase III randomized trial of gadolinium texaphyrin (PCI-0120) as a radiosensitizer in patients with brains metastases receiving whole brain radiotherapy
. 2(10), 698-699.
Mehta, M. (2001). Phase III randomized trial of gadolinium texaphyrin (PCI-0120) as a radiosensitizer in patients with brains metastases receiving whole brain radiotherapy
. 2(10), 698-699.
As the field of oncology continues to move towards its aim of transforming cancer into a curable and perhaps preventable disease, clinical trials take on an ever increasing importance. The Oncology Spectrums "Oncology Clinical Trials Report" provides an inside view into cancer clinical trials, including the challenges and successes in the design and execution of these studies. This column also provides a forum for discussion of cancer clinical trials, as well as news on current developments in clinical trials for specific types of cancer. This month's installment of the "Oncology Clinical Trials Report" covers a recently completed trial for brain metastases patients receiving radiotherapy.